Cour Pharma
5 known investors
COUR develops antigen-specific immunotherapies that reprogram the immune system to treat the underlying causes of autoimmune and immune-mediated diseases while preserving normal immune function. The company is advancing a pipeline of disease-modifying therapies aimed at patients with a range of autoimmune conditions.
Investors Β· 5
Competitors Β· 3
by search overlap
Collegium Pharmaceutical34 shared keywordsCollegium Pharmaceutical is a biopharmaceutical company developing a portfolio of medications to treat serious medical conditions. It serves patients living with serious medical conditions and the healthcare professionals caring for them.
Kite Pharma30 shared keywordsKite Pharma develops CAR T-cell therapies for cancer patients, engineering the immune system's cells to target and attack cancer. Each therapy is individualized per patient through a multi-step manufacturing process.
Bioworld29 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Companies competing with Cour Pharma for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Cour Pharma do?
- COUR develops antigen-specific immunotherapies that reprogram the immune system to treat the underlying causes of autoimmune and immune-mediated diseases while preserving normal immune function. The company is advancing a pipeline of disease-modifying therapies aimed at patients with a range of autoimmune conditions.
- Who are Cour Pharma's investors?
- Cour Pharma's investors include Alpha Wave Global, Lumira Ventures, Roche Venture Fund, Angelini Ventures, JDRF T1D Fund.